Company Overview
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
Recent News
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Propanc Biopharma Provides Shareholder Update
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Stock Overview
09/03/2025 08:00 PM EDT
Investor Relations
Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com